Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.

Provided herein are novel 3-pyrrolidineindole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis and mental illnesses such as depression and post-traumatic stress disorder, and processes for preparing such compounds.

Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.

Provided herein are novel TYK2 inhibitors, pharmaceutical compositions, use of such compounds in treating autoimmune and inflammatory diseases, and processes for preparing such compounds.

Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.

Provided herein are novel ergoline compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders such as depressive disorders and bipolar disorders, and processes for preparing such compounds.

Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.

Provided herein are novel bicyclic heterocyclic compounds as CD73 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Novel Compounds as CDK2 Inhibitors for Treating Cancer.

Provided herein are novel compounds as CDK2 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.